Canakinumab
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB06168 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 100 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | hepatic infarction | KG + DL |
| 2 | hepatic veno-occlusive disease | KG + DL |
| 3 | peliosis hepatis | KG + DL |
| 4 | syndrome with combined immunodeficiency | KG + DL |
| 5 | periodic fever-infantile enterocolitis-autoinflammatory syndrome | KG + DL |
| 6 | familial Mediterranean fever, autosomal dominant | KG + DL |
| 7 | extracutaneous mastocytoma | KG + DL |
| 8 | Blau syndrome | KG + DL |
| 9 | monosomy X | KG + DL |
| 10 | liver angiosarcoma | KG + DL |
| 11 | aggressive systemic mastocytosis | KG + DL |
| 12 | X-linked lymphoproliferative disease due to SH2D1A deficiency | KG + DL |
| 13 | primary release disorder of platelets | KG + DL |
| 14 | pseudo-von Willebrand disease | KG + DL |
| 15 | hepatic veno-occlusive disease-immunodeficiency syndrome | KG + DL |
| 16 | systemic mastocytosis | KG + DL |
| 17 | chromhidrosis | KG + DL |
| 18 | combined immunodeficiency due to CRAC channel dysfunction | KG + DL |
| 19 | pancytopenia due to IKZF1 mutations | KG + DL |
| 20 | A20 haploinsufficiency | KG + DL |
| 21 | hidradenitis | KG + DL |
| 22 | indolent systemic mastocytosis | KG + DL |
| 23 | Smouldering systemic mastocytosis | KG + DL |
| 24 | lymphoadenopathic mastocytosis with eosinophilia | KG + DL |
| 25 | mastocytosis | KG + DL |
| 26 | proteosome-associated autoinflammatory syndrome | KG + DL |
| 27 | immune dysregulation with inflammatory bowel disease | KG + DL |
| 28 | pyogenic arthritis-pyoderma gangrenosum-acne syndrome | KG + DL |
| 29 | periodic fever syndrome | KG + DL |
| 30 | enthesitis-related juvenile idiopathic arthritis | KG + DL |
| 31 | rheumatoid factor-negative juvenile idiopathic arthritis | KG + DL |
| 32 | absent thumb-short stature-immunodeficiency syndrome | KG + DL |
| 33 | facial dysmorphism-immunodeficiency-livedo-short stature syndrome | KG + DL |
| 34 | primary immunodeficiency due to a genetic defect in innate immunity | KG + DL |
| 35 | autoinflammatory syndrome with pyogenic bacterial infection and amylopectinosis | KG + DL |
| 36 | hepatic vein thrombosis | KG + DL |
| 37 | Budd-Chiari syndrome | KG + DL |
| 38 | primary immunodeficiency due to a defect in adaptive immunity | KG + DL |
| 39 | immuno-osseous dysplasia | KG + DL |
| 40 | Glanzmann thrombasthenia | KG + DL |
| 41 | ankylosing spondylitis | KG + DL |
| 42 | heme oxygenase 1 deficiency | KG + DL |
| 43 | autosomal dominant macrothrombocytopenia | KG + DL |
| 44 | hidradenitis suppurativa | KG + DL |
| 45 | inflammatory spondylopathy | KG + DL |
| 46 | spondyloarthropathy, susceptibility to | KG + DL |
| 47 | CINCA syndrome | KG + DL |
| 48 | dyshidrosis | KG + DL |
| 49 | pyogenic autoinflammatory syndrome | KG + DL |
| 50 | fetal and neonatal alloimmune thrombocytopenia | KG + DL |
(Showing top 50 of 100 predictions)
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.